TSMHT
VRTX icon

Thurston Springer Miller Herd & Titak’s Vertex Pharmaceuticals VRTX Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Hold
63
– – 0.01% 573
2026
Q1 		$28.1K Sell
63
-13
-17% -$6.06K 0.01% 678
2025
Q4 		$34.5K Sell
76
-164
-68% -$70.7K 0.01% 586
2025
Q3 		$94K Sell
240
-2,487
-91% -$1.04M 0.19% 146
2025
Q2 		$1.21M Buy
2,727
+553
+25% +$255K 0.16% 151
2025
Q1 		$1.05M Buy
2,174
+405
+23% +$189K 0.18% 129
2024
Q4 		$712K Buy
1,769
+673
+61% +$312K 0.14% 151
2024
Q3 		$510K Buy
1,096
+175
+19% +$84.1K 0.14% 161
2024
Q2 		$432K Buy
+921
New +$400K 0.13% 157

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's VRTX Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 63 shares worth $31.3K. The position accounts for 0.01% of the portfolio, ranked #573.

Thurston Springer Miller Herd & Titak first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.21M in Q2 2025. 299 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Thurston Springer Miller Herd & Titak held 63 shares of Vertex Pharmaceuticals worth $31.3K as of Q2 2026.
  • Thurston Springer Miller Herd & Titak left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #573 holding.
  • Thurston Springer Miller Herd & Titak first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Thurston Springer Miller Herd & Titak's Vertex Pharmaceuticals position peaked at $1.21M in Q2 2025.
  • 299 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.